Anzeige
Erschienen in:
15.09.2020 | Systematic Review
Laser Treatment for Non-Melanoma Skin Cancer: A Systematic Review and Meta-Analysis
Erschienen in: American Journal of Clinical Dermatology | Ausgabe 1/2021
Einloggen, um Zugang zu erhaltenAbstract
Background
Surgery is the mainstay of treatment for non-melanoma skin cancer. Lasers are an additional option.
Objective
The objective of this study was to review the literature on the efficacy and safety of lasers for the treatment of non-melanoma skin cancer.
Methods
A systematic review and meta-analysis of laser treatment for non-melanoma skin cancer was performed. The primary outcome was recurrence rate (RR).
Results
The review included 32 studies (six randomized controlled trials and 26 cohort studies): 27 evaluated basal cell carcinomas (BCCs), three squamous cell carcinomas, and two both, for a total of 4755 BCCs and 214 squamous cell carcinoas. Most BCCs were low risk. The Nd:YAG laser (seven studies, 3286 BCCs) had a 3.1% RR (95% confidence interval [CI] 1.4–6.4%) during a mean follow-up of 7.9 years, with a low rate (< 20%) of scarring and dyspigmentation. The CO2 laser (ten studies, 904 BCCs) had a 9.4% RR (95% CI 4.1–20) during a mean follow-up of 2.1 years, with a low rate of side effects. The pulsed dye laser (eight studies, 206 BCCs) had a 38% RR (95% CI 24–55). In two studies, the Nd:YAG laser demonstrated a RR of 10% (95% CI 2–31) for Bowen’s disease, and in three studies, the CO2 laser demonstrated a RR of 22% (95% CI 5–61) for squamous cell carcinoma.
Conclusions
Based on cohort studies, the Nd:YAG laser is a safe and efficacious modality for the treatment of low-risk BCC. Based on settings applied in prior studies in the literature, the CO2 laser is less efficacious than the Nd:YAG laser, thus it cannot be recommended for BCC treatment. Insufficient data preclude conclusions regarding laser treatment for squamous cell carcinoma.
Registration
PROSPERO registration number CRD42019129717.